MCARH171
Drug
Celgene Corporation
Total Payments
$17,242
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $17,242 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,242 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma (MCARH171 MM-Mono&Len) | Celgene Corporation | $17,242 | 0 |
Top Doctors Receiving Payments for MCARH171
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $17,242 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $17,242
Product Information
- Type Drug
- Total Payments $17,242
- Total Doctors 0
- Transactions 1
About MCARH171
MCARH171 is a drug associated with $17,242 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $17,242 was paid across 1 transactions to 0 doctors.
The most common payment nature for MCARH171 is "Unspecified" ($17,242, 100.0% of total).
MCARH171 is associated with 1 research study, including "Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma (MCARH171 MM-Mono&Len)" ($17,242).